Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Bernstein analysts reaffirmed their Market Perform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on May 20, ...

Recently, BioNTech SE announced an $800 million acquisition of Biotheus ... subject to customary regulatory approvals and 3SBio shareholder consent. Upon completion, Pfizer will also make a $100 ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

Pfizer has signed a worldwide licensing agreement, excluding China, with biopharmaceutical company 3SBio to develop, manufacture and commercialise bispecific antibody targeting programmed cell ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...

Pfizer Inc. announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to ...